IL27 and melanoma: Accordingly, results obtained in murine models of plasmacytoma, melanoma, and neuroblastoma showed that both systemic and intratumorally delivered IL-27 enhanced presence of CD8+ CTLs in tumor microenvironment which resulted in the tumor regression [19].